drugset / Trial / NCT00202696

Nalmefene Smoking Cessation Study

NCT00202696

Phase 2 Completed 76 enrolled Somaxon Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

To determine if nalmefene is safe and effective in smoking cessation.

Timeline

Start
2005-09
Primary completion
2006-03
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Nalmefene Small molecule 40 mg Oral
Subject Nalmefene Small molecule 80 mg Oral

Indications

No indication recorded.